Researchers are turning to some unlikely allies in the fight against cancer: dogs, ancient DNA, and simple blood draws. At a recent symposium hosted by the V Foundation for Cancer Research, scientists unveiled promising approaches that could transform how cancers are detected and treated in both humans and animals.
One of the most striking developments comes from canine research. Dr. Robert Canter, a surgical oncologist, noted that dogs and humans develop many of the same cancers, and their responses to therapy are strikingly similar. His team is now studying natural killer (NK) cell therapy, which uses the body's own immune cells to find and destroy tumors. The work aims to improve immunotherapy outcomes for both species, potentially accelerating treatments that benefit pets and their owners simultaneously.
In a separate breakthrough, Dr. Ami Bhatt described a novel approach to engineering immune cells using precise, DNA-pasting enzymes. Her lab is developing methods to convert normal T cells in the body into CAR-T cells, which are genetically programmed to recognize and kill cancer. By borrowing strategies from the most evolved organisms on Earth, the team hopes to create therapies that are more effective and less toxic than current options.
Perhaps the most urgent progress involves pediatric brain tumors, which remain the number one cause of cancer deaths in children. Dr. Shannon Stott's laboratory is now receiving pediatric patient blood samples from multiple cancer centers across the country, creating a national collaboration. Using this resource, her team has successfully detected brain tumor signals with a simple blood test, offering an alternative to invasive procedures like spinal taps or surgical biopsies. For families, this means earlier detection, better treatment guidance, and less trauma for young patients.
From Laboratory to Lifesaving
The research presented at the Krzyzewski Family Cancer Research Symposium reflects a broader shift in oncology: moving away from one-size-fits-all treatments toward personalized, biology-driven therapies. Each project, while distinct, shares a common thread of turning natural biological processes into medical interventions.
Susanna Fletcher Greer, Chief Scientific Officer at the V Foundation, emphasized the stakes during the event, recalling the late Jim Valvano's famous words: "Cancer research is our only hope for a cure." She noted that every discovery begins with a question, and the scientists funded by the foundation are turning those questions into tangible progress for patients.
What comes next is equally promising. The canine NK cell therapy is moving toward clinical trials that could benefit both dogs and humans, while the blood test for pediatric brain tumors is being refined for broader use across hospitals. The DNA-pasting enzyme technique is still in early stages, but it represents a new frontier in gene editing for cancer immunotherapy.
For patients and families, the message is hopeful: the gap between laboratory breakthroughs and bedside care is narrowing. With collaborations now spanning veterinary medicine, genetics, and pediatric oncology, the future of cancer care looks increasingly precise, less invasive, and more compassionate.